A one-stop approach resulted in a new diagnosis of HF for 3% of the clinic’s visitors, who then were referred for timely ...

PRESTIGE-AF is the first of the larger trials in this scenario to report results. More data are needed to help guide ...

Seeing is believing. Patients shown proof of calcification adhered better to statins; those without CAC avoided overtreatment ...

Martha Gulati and Kathyn Berlacher talk about tangible ways to improve women's cardiovascular care, including nontraditional, patient-centered solutions.

Procedural planning and attention to detail can help, but heart teams should be realistic about what lies ahead, experts say.

Even with recommendations in place, hospitals were far from uniform in their anticoagulation approaches well into 2022.

Talking with C. Michael Gibson, David Austin reviews the phase III trial of enalapril for anthracycline-induced cardiotoxicity in lymphoma and breast cancer patients.